Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
European Society for Medical Oncology (ESMO)
ESMO 2014 – Prostate Cancer
ESMO 2014 – Prostate Cancer
Sequencing Abiraterone Acetate, Cabazitaxel, and Enzalutamide in Post-Docetaxel mCRPC: Exploiting Efficacy and Avoiding Cross-Resistance
ESMO 2014 – Prostate Cancer
Read More ›
Emerging Agents for Metastatic Prostate Cancer: Galeterone, Selinexor, and ARN-509
ESMO 2014 – Prostate Cancer
Read More ›
Early PSA Response as a Prognostic Factor in Metastatic Prostate Cancer
ESMO 2014 – Prostate Cancer
Read More ›
Adding Docetaxel to ADT Significantly Improves Survival versus ADT Alone in Patients with High-Volume Metastatic Prostate Cancer
ESMO 2014 – Prostate Cancer
Read More ›
Androgen Receptor and CYP17A1 Copy Number Variations as Predictors of Outcomes in Patients with Metastatic Prostate Cancer Receiving Abiraterone
ESMO 2014 – Prostate Cancer
Read More ›
Updated STRIDE and STAND Trial Results: Optimal Sipuleucel-T Use in Metastatic Prostate Cancer
ESMO 2014 – Prostate Cancer
Read More ›
AR-V7 Splice Variant as Prognostic Marker for Resistance to Enzalutamide or Abiraterone in Men with Metastatic Prostate Cancer
ESMO 2014 – Prostate Cancer
Read More ›
Chemohormonal Therapy versus Hormonal Therapy Alone in Men with Metastatic Prostate Cancer
ESMO 2014 – Prostate Cancer
Read More ›
Maximal Androgen Depletion with Abiraterone Acetate Followed by Molecular-Targeted Therapies in Metastatic Prostate Cancer: Finding an Androgen-Signaling Signature to Predict Response
ESMO 2014 – Prostate Cancer
Read More ›
Enzalutamide Long-Term Safety and Efficacy in Hormone-Naïve Prostate Cancer
ESMO 2014 – Prostate Cancer
Read More ›
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us